466. All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)

BACKGROUND: There are limited oral antifungal treatment options for patients with high-mortality fungal infections such as candidemia or invasive candidiasis who fail available antifungals or have infection caused by resistant fungi. Ibrexafungerp is a broad-spectrum glucan synthase inhibitor with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Prattes, Juergen, King, Thomas, Azie, Nkechi, Angulo, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752405/
http://dx.doi.org/10.1093/ofid/ofac492.524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752405/
http://dx.doi.org/10.1093/ofid/ofac492.524

Ejemplares similares